Pipeline Overview

To date, DEINOVE is the only French biotech with a small molecule in Phase II clinical development, fully owned by the company, in the field of antibiotics.

DEINOVE builds a portfolio of first-in-class antimicrobial candidates, which places it among the major players in the field, by bringing together a European network of expertise.

Clostridioides difficile severe infections

intravenous administration
Discovery
Optimization
Preclinical
Phase I
Phase II
Phase III

Anthrax and Tularemia

Evaluated by the United States Army Medical Research Institute of Infectious Diseases
Discovery
Optimization
Preclinical
Phase I
Phase II
Phase III

An "Investments for the Future" Program

Discovery
Optimization
Preclinical
Phase I
Phase II
Phase III

A class of dual activity antibiotics

Discovery
Optimization
Preclinical
Phase I
Phase II
Phase III